DHL

2-AMINO-ETHANETHIOL

DHL in polymers: 1 entry. Examples include: 5APR

DHL as a free ligand exists in 6 entries. Examples include: 3SOM 2Y8D 4CG4

Find related ligands: Stereoisomers Similar ligands Chemical Structure Search

View summary at Ligand Expo



Chemical Component Summary

Name2-AMINO-ETHANETHIOL
Identifiers2-aminoethanethiol
FormulaC2 H7 N S
Molecular Weight77.15
TypeL-PEPTIDE LINKING
Isomeric SMILESNCCS
InChIInChI=1S/C2H7NS/c3-1-2-4/h4H,1-3H2
InChIKeyUFULAYFCSOUIOV-UHFFFAOYSA-N

Chemical Details

Formal Charge0
Atom Count11
Chiral Atom Count0
Chiral Atomsn/a
Bond Count10
Aromatic Bond Count0
Leaving Atomsn/a

Drug Info: DrugBank

DrugBank IDDB00847 Different stereochemistry
NameCysteamine
Groups
  • approved
  • investigational
DescriptionCysteamine is a radiation-protective agent that oxidizes in air to form cystamine. It can be given intravenously or orally to treat radiation sickness. The bitartrate and hydrochloride salt forms are indicated for the treatment of neuropathic cystinosis in patients 6 years old and older. [PubChem]. Cysteamine is marketed under several brand names such as Cystaran™, Procysbi, and Cystagon®.
Synonyms
  • 2-Amino-1-ethanethiol
  • 2-AMINO-ethanethiol
  • 2-Aminoethanethiol
  • beta-Aminoethanethiol
  • beta-Aminoethylthiol
Salts
  • Cysteamine Bitartrate
  • Cysteamine Hydrochloride
Brand Names
  • Cystagon
  • Cystaran
  • Procysbi Delayed-release
  • Procysbi
Affected OrganismHumans and other mammals
IndicationGiven intravenously or orally to treat radiation sickness. The bitartrate salts (Cystagon® and Procysbi) have been used for the oral treatment of nephropathic cystinosis and cystinurea. The hydrochloride salt (Cystaran™) is indicated for the treatment of corneal cystine crystal accumulation in cystinosis patients.
PharmacologyPeople born without the ability to metabolize the amino acid cystine suffer from cystinosis, a rare inherited disorder characterized by the deposition and accumulation of cystine crystals throughout the body. These crystals cause considerable damage, particularly in the kidney and eye. Kidney failure can occur by the age of 10 in untreated patients. Cysteamine prevents the accumulation of cystine crystals and is prescribed to prevent further kidney and eye damage. Cysteamine helps to convert cystine into less harmful chemical forms that can be removed from cells.
Mechanism of actionThe free thiol cysteamine depletes cystinotic leukocytes and other cells of cystine, whose accumulation is considered the cause of organ damage in cystinosis. Cysteamine cleaves the disulfide bond with cystine to produce molecules that can escape the metabolic defect in cystinosis and cystinuria.
Route of administration
  • Ophthalmic
  • Oral
Categories
  • Alimentary Tract and Metabolism
  • Amines
  • Amino Acids and Derivatives
  • Chemical Actions and Uses
  • Cystine Depleting Agents
ATC-Code
  • S01XA21
  • A16AA04
CAS number60-23-1

Drug Targets

NameSequence SearchPharmacological ActionActions
SomatostatinMLSCRLQCALAALSIVLALGCVTGAPSDPRLRQFLQKSLAAAAGKQELAK...unknownbinder
Neuropeptide Y receptor type 2MGPIGAEADENQTVEEMKVEQYGPQTTPRGELVPDPEPELIDSTKLIEVQ...unknownother/unknown
unknowncleavage
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682